Doliver Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.11M | Buy |
4,413
+1
| +0% | +$215 | 0.25% | 65 |
|
|
2026
Q1 | $960K | Buy |
4,412
+1
| +0% | +$222 | 0.22% | 72 |
|
|
2025
Q4 | $1.01M | Sell |
4,411
-620
| -12% | -$141K | 0.25% | 74 |
|
|
2025
Q3 | $1.16M | Buy |
5,031
+2
| +0% | +$407 | 0.3% | 60 |
|
|
2025
Q2 | $934K | Sell |
5,029
-44
| -0.9% | -$8.18K | 0.26% | 70 |
|
|
2025
Q1 | $1.06M | Sell |
5,073
-203
| -4% | -$39.5K | 0.3% | 58 |
|
|
2024
Q4 | $938K | Buy |
5,276
+59
| +1% | +$10.8K | 0.26% | 62 |
|
|
2024
Q3 | $1.03M | Sell |
5,217
-949
| -15% | -$177K | 0.28% | 58 |
|
|
2024
Q2 | $1.06M | Buy |
6,166
+2
| +0% | +$331 | 0.3% | 58 |
|
|
2024
Q1 | $1.12M | Sell |
6,164
-8
| -0.1% | -$1.38K | 0.32% | 58 |
|
|
2023
Q4 | $957K | Buy |
6,172
+2
| +0% | +$292 | 0.29% | 61 |
|
|
2023
Q3 | $920K | Sell |
6,170
-468
| -7% | -$68.7K | 0.28% | 63 |
|
|
2023
Q2 | $894K | Sell |
6,638
-118
| -2% | -$17.3K | 0.27% | 67 |
|
|
2023
Q1 | $1.08M | Buy |
6,756
+2
| +0% | +$306 | 0.34% | 52 |
|
|
2022
Q4 | $1.09M | Buy |
6,754
+1
| +0% | +$153 | 0.36% | 46 |
|
|
2022
Q3 | $906K | Sell |
6,753
-503
| -7% | -$72.2K | 0.33% | 52 |
|
|
2022
Q2 | $1.11M | Sell |
7,256
-1,789
| -20% | -$273K | 0.39% | 44 |
|
|
2022
Q1 | $1.47M | Sell |
9,045
-5,284
| -37% | -$768K | 0.46% | 36 |
|
|
2021
Q4 | $2.02M | Sell |
14,329
-3,186
| -18% | -$376K | 0.63% | 21 |
|
|
2021
Q3 | $1.89M | Buy |
17,515
+1,332
| +8% | +$152K | 0.63% | 23 |
|
|
2021
Q2 | $1.82M | Buy |
16,183
+723
| +5% | +$81.4K | 0.6% | 23 |
|
|
2021
Q1 | $1.67M | Buy |
15,460
+1,124
| +8% | +$120K | 0.62% | 27 |
|
|
2020
Q4 | $1.54M | Buy |
14,336
+1,028
| +8% | +$98.8K | 0.68% | 27 |
|
|
2020
Q3 | $1.17M | Buy |
13,308
+460
| +4% | +$43.3K | 0.59% | 30 |
|
|
2020
Q2 | $1.26M | Buy |
12,848
+189
| +1% | +$16.6K | 0.56% | 33 |
|
|
2020
Q1 | $1.07M | Sell |
12,659
-1,432
| -10% | -$122K | 0.53% | 33 |
|
|
2019
Q4 | $1.25M | Sell |
14,091
-86
| -0.6% | -$7.14K | 0.49% | 32 |
|
|
2019
Q3 | $1.06M | Buy |
14,177
+751
| +6% | +$51.5K | 0.42% | 36 |
|
|
2019
Q2 | $976K | Buy |
13,426
+190
| +1% | +$14.9K | 0.38% | 30 |
|
|
2019
Q1 | $1.07M | Buy |
13,236
+571
| +5% | +$46.7K | 0.43% | 26 |
|
|
2018
Q4 | $1.17M | Sell |
12,665
-297
| -2% | -$26.1K | 0.57% | 16 |
|
|
2018
Q3 | $1.23M | Buy |
12,962
+1,144
| +10% | +$108K | 0.51% | 23 |
|
|
2018
Q2 | $1.09M | Buy |
11,818
+431
| +4% | +$42.1K | 0.46% | 22 |
|
|
2018
Q1 | $1.08M | Sell |
11,387
-599
| -5% | -$65.8K | 0.47% | 21 |
|
|
2017
Q4 | $1.16M | Sell |
11,986
-1,030
| -8% | -$97.1K | 0.46% | 24 |
|
|
2017
Q3 | $1.16M | Buy |
13,016
+2,329
| +22% | +$177K | 0.52% | 35 |
|
|
2017
Q2 | $775K | Buy |
+10,687
| New | +$718K | 0.37% | 62 |
|
Other funds holding ABBV
Doliver Advisors's ABBV Position: Q2 2026 in Review
Doliver Advisors increased its AbbVie (ABBV) stake by 0.02% in Q2 2026, buying an estimated $215 and bringing the position to 4,413 shares worth $1.11M. The position accounts for 0.25% of the portfolio, ranked #65.
Doliver Advisors first reported a position in ABBV in Q2 2017 and has held it in 37 quarters since. The position peaked at $2.02M in Q4 2021. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Doliver Advisors held 4,413 shares of AbbVie worth $1.11M as of Q2 2026.
- Doliver Advisors bought 1 AbbVie share in Q2 2026, an estimated $215.
- AbbVie made up 0.25% of Doliver Advisors's portfolio in Q2 2026, its #65 holding.
- Doliver Advisors first reported a position in AbbVie in Q2 2017 and has held it in 37 quarters since.
- Doliver Advisors's AbbVie position peaked at $2.02M in Q4 2021.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Doliver Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.